

AD _____

GRANT NUMBER: DAMD17-94-J-4171

TITLE: β -Catenin Stability in Breast Cancer

PRINCIPAL INVESTIGATOR(S): Vijay Easwaran

CONTRACTING ORGANIZATION: Georgetown University
Washington DC 200057

REPORT DATE: July 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1997		3. REPORT TYPE AND DATES COVERED Annual (15 Jun 96 - 14 Jun 97)
4. TITLE AND SUBTITLE β-Catenin Stability in Breast Cancer			5. FUNDING NUMBERS DAMD17-94-J-4171	
6. AUTHOR(S) Byers, Stephen, Ph.D. Easwaran, Vijay				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited <div style="text-align: right; font-size: 2em; font-weight: bold;">19980601 039</div>				
13. ABSTRACT (Maximum 200 words) β-catenin is a critical signaling molecule that participates in differentiation and proliferation pathways. Cytoplasmic β-catenin participates in intracellular signaling via the LEF/TCF family of transcriptional activators. Mutations that lead directly or indirectly to stabilization of cytoplasmic β-catenin are oncogenic. We hypothesize that the cytoplasmic, "signaling" pool of β-catenin is regulated at the level of protein stability by the ubiquitin-proteasome degradation pathway. The tumor suppressor adenomatous polyposis coli (APC) gene product has been reported to associate with β-catenin and effect its down-regulation by an unknown mechanism. We hypothesize that APC is an ubiquitin-ligase (E3 enzyme) that helps ubiquitinate β-catenin and target it to the proteasome for degradation. We propose to test our hypotheses <i>in vitro</i> using cell-free reconstitution assays. <i>In vivo</i> studies include transient transfections with APC constructs that possess or lack the free-cysteine HECT consensus which is characteristic of ubiquitin ligases. Cytoplasmic β-catenin levels in the transfectants will be monitored in response to specific proteasomal inhibitors that will cause the β-catenin to accumulate as ubiquitinated conjugates. Finally, the physiological activity of GSK3β on APC phosphorylation, and subsequent effects on β-catenin ubiquitination and stability will be addressed.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 21	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

2-9-98
Date

TABLE OF CONTENTS:

Front Cover	1
SF298 Report Documentation Page	2
Foreword	3
Table of contents	4
Introduction	
Relevance and Nature of Problem	5
Background	5
Hypotheses to be Tested	8
Methods	8
Results	10
Conclusions and Recommended Changes	11
Bibliography	12
Addenda	16

INTRODUCTION

Relevance and Nature of Problem

One in 8 American women will develop breast cancer in her lifetime. Despite the advances in detection and treatment of breast cancer, the mortality from breast cancer has not changed significantly over the last forty years. Breast cancer treatments significantly include radiation and chemotherapy. These regimens are acutely limited by the lack of ability to specifically target tumor cells. The emotional state of the patient which could be a critical factor in combating the disease is gravely debilitated by the psychosomatic trauma of these severe treatment procedures. Even those patients that survive, face the possibility of remission and an uncertain future. Unlike the survival after many other cancers, which tend to level off after 5 years, survival after diagnosis of breast cancer continues to decline. Even women who try to make preventive life-style changes cannot alter the most significant risk factors like age or family history. In this grim scenario, a basic understanding of the cellular processes underlying breast cancer is mandated before effective therapies can be developed or even attempted.

β -catenin is a multifunctional protein that primarily helps link the cadherins (at the adherens junctions) to the cytoskeleton. However, β -catenin is also a crucial signaling molecule that participates in differentiation and proliferation pathways. The *wnt* signaling pathway, known to reverse contact inhibition in mouse mammary cells *in vitro* and to cause mammary cancer in mice (7), results in increased levels of cytoplasmic β -catenin (8). *Wnt*-1 stimulation results in decreased activity of glycogen synthase kinase (GSK)-3 β , that normally phosphorylates the tumor suppressor adenomatous polyposis coli (APC) gene product (8,9). When APC is not phosphorylated, it leads to the stabilization of β -catenin. The stable β -catenin interacts with the transcriptional activators LEF/TCF (10). The β -catenin-TCF/LEF complex translocates to the nucleus and effects gene expression (1,2). The genes activated may include those that stimulate proliferation or antagonize apoptosis (11,12). And finally, stable forms of β -catenin by themselves are oncogenic (3,12,13). These observations strongly point towards the stability of cytoplasmic β -catenin as a “smoking gun” (12) linking cell adhesion and tumorigenesis. Thus, a strategy of down-regulating β -catenin could constitute a potential way of treating breast cancer.

In this study, we investigate the regulation of cytoplasmic β -catenin.

Background


β - Catenin and breast cancer

Cells touch one another through a number of different surface molecules; among the most intriguing are the cadherins and their associated proteins (14). These proteins, in addition to maintaining adhesion of adult tissues, via the adherens junctions, are critical during development and tumorigenesis (15). Cadherin function has been shown to depend on several associated proteins, namely; α , β , and (plakoglobin) γ catenin (16). These molecules, link cadherins to the actin cytoskeleton and are probably involved in relaying cadherin-mediated-contact signals (17).

The β -catenin/cadherin association requires serine phosphorylation of the cadherin molecule (17). β -catenin is itself a substrate for tyrosine phosphorylation and can also act as a link between Growth factor receptors (such as the EGFR) and the adherens junction complex (18,19). Mutation of the β -catenin gene in mice, by homologous recombination, results in embryonal lethality. When the expression of E-cadherin and the catenins was analyzed in human breast carcinomas, lobular breast carcinomas showed disturbances of E-cadherin and catenins in a high frequency of cases (20). In ductal breast carcinomas (where E-cadherin is often unchanged), a high frequency of cases showed disturbance of alpha- and/or gamma-catenin expression. 50 % of cases with defects in E-cadherin and catenins had lymph node metastasis, whereas this number was low in cases with undisturbed cadherin/catenin expression (20).

A truncated stable form of β -catenin itself acts as an oncogene (9). The phosphorylation state of β -catenin can also influence the transformed phenotype (19,21). Further, cytoplasmic β -catenin associates with the tumor suppressor adenomatous polyposis coli (APC) gene product (19). Over-expression of APC results in the cell cycle being blocked at the G1/S boundary (19). Recent evidence indicating that the tumor suppressor effects of APC are dependent upon its ability to destabilize β -catenin, strongly argue the significance of β -catenin in the control of cell proliferation (5,22).

β -catenin is a signaling molecule



β -catenin participates in developmental patterning in *Xenopus* (23). Ectopic expression of β -catenin by mRNA injection into the ventral region of *Xenopus* embryos induces a secondary dorso-anterior body axis, giving rise to two heads, notochords, and neural tubes (24). Wnt-1, the vertebrate homologue of wingless is known to reverse contact inhibition in mouse mammary cells *in vitro* and to cause breast cancer in mice (24). Wnt-1 stimulation results in decreased activity of glycogen synthase kinase (GSK)-3 β , that normally phosphorylates the tumor suppressor adenomatous polyposis coli (APC) gene product (5,8). When APC is not

phosphorylated, it leads to the stabilization of β -catenin through an unknown mechanism. Now, β -catenin interacts with transcriptional activators LEF/TCF, translocates to the nucleus, and effects gene expression (10,25). The genes activated may include those that stimulate proliferation or antagonize apoptosis.

Taken together, these finding strongly argue the significance of β -catenin and its cytoplasmic levels in the integration of adhesion, differentiation and proliferation pathways. A clearer understanding of this crucial signaling pathway holds tremendous potential to offer realistic strategies to combat breast cancer.


β -catenin stability and APC

The Adenomatous polyposis Coli (APC) gene is a tumor suppressor, found mutated in most human colon cancers. APC directly binds β -catenin (26). APC is a part of the *wnt* signaling pathway, and when phosphorylated by GSK3 β , down-regulates β -catenin levels. Cancer cells with mutant APC contain abnormally high levels of cytoplasmic β -catenin (4,5). Over-expression of APC blocks progression of the cell cycle from G₀ to the S phase (27). This observation suggests that loss APC activity (resulting in β -catenin stabilization) could lead to uncontrolled cellular proliferation. Indeed, the *wnt* signal, thought to inactivate APC, can cause cell proliferation in certain tissues. Although APC has been primarily studied in colon cancer, there is strong evidence that loss of heterozygosity at the APC locus may be involved in mammary tumors in humans. The Multiple intestinal neoplasia (Min) allele is a mutant allele of the murine APC locus. Min-/+ mice are predisposed not only to intestinal but mammary carcinoma as well (7). Among Min-/+ mice exposed to carcinogenic material, over 75% developed mammary tumors, while Min +/+ mice displayed no evidence of mammary tumors (7). These observations suggest that APC, by virtue of its ability to regulate β -catenin, can play an important role in predisposing breast tissue for further hyperplastic events (11).

The ubiquitin-proteasome pathway

Our preliminary evidence demonstrates that the cytoplasmic, “signaling pool” of β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.

The ubiquitin-proteasome pathway is involved in the processing and rapid degradation of many short-lived regulatory proteins. Mitotic cyclins, cyclin-dependent kinase inhibitors, the tumor suppressor p53, transcriptional activators NF- κ B, v-jun, and v-fos are examples of proteins that are degraded by this highly specific pathway (28-31).



The ubiquitin pathway effects the degradation of proteins in two steps (28). First, multiple ubiquitin moieties are covalently attached to a target protein. Second, the multi-ubiquitinated protein is degraded by the 26S proteasome complex. Conjugation of ubiquitin moieties, to a substrate, is performed in a three-step process. Following activation of the C-terminal glycine of ubiquitin by enzyme E1, one of several E2 enzymes transfers the activated ubiquitin to the

substrate that is specifically bound to an enzyme E3.

E3 catalyzes the formation of an isopeptide bond between the activated glycine on the ubiquitin and ϵ -NH₂ group of a lysine residue in the substrate (or in the previously conjugated ubiquitin moiety). The E2 and E3 enzymes bind the substrate, and help transfer the ubiquitin moieties. There are dozens of genes, unrelated to each other, that encode E2 and E3 enzymes. The specificity of the ubiquitin pathway is thought to reside in the E3 enzymes (28). Following

targeting (e.g. phosphorylation, as in the case of NF- κ B) and multi-ubiquitination, the substrate protein is rapidly degraded by a large multi-subunit structure called the proteasome.

PURPOSE

The general aim of this investigation is to study the regulation of cytoplasmic β -catenin stability, and the involvement of the tumor suppressor APC in this process.

Our **working model** is that β -catenin is recruited by a cadherin to the plasma membrane where it is phosphorylated on serine residues (analogous to I κ B). This phosphorylated β -catenin can either be recruited to an adhesion complex or can interact with APC via its armadillo domains. In the presence of active GSK3 β , APC is phosphorylated and its E3 activity is activated. β -catenin is also phosphorylated by GSK3 β . In response to these events, β -catenin is ubiquitinated and degraded by the proteasome. When APC or β -catenin or both are mutated, the result is accumulation of cytoplasmic β -catenin. At elevated levels, cytoplasmic β -catenin is oncogenic.

SPECIFIC AIMS (Years 1-2)

Year 1 (presented in annual report - 1996):

Aim 1. To test the hypothesis that cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.

Aim 2. To establish an *in vitro* cell-free model to study β -catenin ubiquitination and degradation

Year 2:

Aim 3. To test the hypothesis that the tumor suppressor adenomatous polyposis coli (APC) is involved in the ubiquitin-proteasome pathway that regulates β -catenin stability (Collaborator: Dr. Paul Polakis)

Aim 4. To test the hypothesis that the APC gene product is an ubiquitin-ligase (E3) that ubiquitinates β -catenin and targets it for degradation by the proteasome (Collaborators: Dr. Aaron Ciechanover, Dr. Allan Weissman, Dr. Richter King)

METHODS

Aim 1. To test the hypothesis that cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.

- The effect of proteasomal inhibitors on cytoplasmic β -catenin stability was tested. The breast cancer cell line SKBR3 (APC+/+) and the colon cancer cell line SW480 (APC-/-) were used in this experiment. Cells were treated with the proteasomal inhibitors (peptidyl aldehydes) ALLN and Lactacystin (32) for 12 hr. Cells were lysed in a hypotonic lysis buffer and dounce homogenized, clarified in a ultracentrifuge (100,000g for 1 hr) to yield the S100 cytoplasmic fraction (free of membranous components). To obtain cytoplasmic fractions including membrane vesicles, the dounced lysate were clarified in a table-top microfuge (10,000g for 10 min).
- The half-life of β -catenin in E36ts20 cells (33), that harbor a temperature sensitive E1 enzyme, was monitored at permissive and non-permissive temperatures

- SKBR3 cells were transiently transfected with His₆-tagged ubiquitin (34) and HA-tagged β -catenin. Cells were treated with/without proteasomal inhibitors, ubiquitinated proteins were purified with Ni-NTA columns (34), and Western blotted with anti-HA antibody (helps distinguish from native β -catenin).

Aim 2. To establish an *in vitro* cell-free model to study β -catenin ubiquitination and degradation.

In vitro ubiquitination and degradation assays will be established according to published protocols (29,35,36).

- Recombinant β -catenin was generated in a combined *in vitro* transcription-translation system (Promega). mRNA synthesized from 2 μ g of template DNA was used in a 100 μ l translation reaction mixture containing 50 μ l of rabbit reticulocyte lysate (RRL).
- Conjugation assays (29,35) are performed essentially as described by Dr. Ciechanover (29,30,32). Briefly, the reaction mixture (30 μ l) consisted of 1 μ l of either programmed RRL containing the HA-tagged β catenin or unprogrammed RRL, 10 μ l SKBR3 hypotonic lysate (5-6 mg/ml) or, 20 ng E1, 20 ng E2 (UbcH5b) and, either 40 ng E3 (E6-AP)(recombinant enzymes were kindly provided by Dr. Allan Weissman) or 40 ng of various APC deletion constructs. 5 μ g ubiquitin, 40 mM Tris HCl (pH 7.6), 5 mM MgCl₂, 2mM DTT, 0.5 μ g of ubiquitin aldehyde (kindly provided by Dr. Keith Wilkinson), 5mM ATP γ S, 10mM Phosphocreatine, and 5 units Phosphocreatine Kinase, were also included in the reaction mixture. In Assays without ATP γ S, 20 mM EDTA, 0.5 μ g of hexokinase and 10 mM 2-deoxyglucose substituted for ATP γ S. Ubiquitination assays were performed for a 1 hr period at 25°C. Degradation assays included ATP (instead of ATP γ S, which cannot be used by the proteasome but can be utilized by the ubiquitination enzymes), and were performed at 37°C for 2 hr. Following incubation, reaction mixtures are resolved by Tris-glycine SDS-PAGE (4-12%).
- Western blotting was performed using anti-HA (BabCo) and anti- β -catenin antibodies (Transduction labs).

Aim 3. To test the hypothesis that the tumor suppressor adenomatous polyposis coli (APC) gene product is involved in the ubiquitin-proteasome pathway that regulates β -catenin.

- *In vitro* ubiquitination assay with SW480 (APC^{-/-}) cytoplasmic fraction and recombinant APC constructs with/without the HECT consensus.
- Test the effects of alkylating agents (alkylating agents like N-ethyl maleimide (NEM) block the free cysteine residues necessary for the thiol-ester transfer of ubiquitin) (36) on the ligase activity of recombinant APC
- Transient transfection of SW480 (APC^{-/-}) cells with APC (4), monitor cytoplasmic β -catenin levels in response to proteasomal inhibitors.

SW480 cells (APC^{-/-}) were co-transfected with a vector encoding His₆-tagged ubiquitin (34) and vector encoding APC 25 (4) (the smallest construct including the free cysteine consensus) or vector alone, using Lipofectamine™ (GIBCO) according to manufacturer's instructions.. 24 hr after transfection, the cells were treated with the proteasome-specific inhibitor, Lactacystin for

6hr. Ubiquitinated proteins were purified by Ni-NTA chromatography, and Western blotted with anti- β -catenin antibody

Aim 4. To test the hypothesis that the APC gene product is an ubiquitin-ligase (E3)

- *In vitro* reconstitution experiments (35-37) with recombinant β -catenin, E1, E2, and various APC constructs with/without the HECT consensus.

RESULTS

Aim 1. To test the hypothesis that cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.

1. Results indicate that treatment of SKBR3 cells with proteasomal inhibitors ALLN and Lactacystin (32) result in the accumulation of high-molecular weight, β -catenin-ubiquitin conjugates in the cytoplasm (Addenda; Fig. 1).
2. E36ts20 cells harboring a thermolabile Ubiquitin activating (E1) enzyme (33), when grown at the non-permissive temperature (39.5°C) accumulate β -catenin (half-life is extended, compared to cells grown at the permissive temperature; 30°C) (Fig. 2).
3. In a more direct approach, SKBR3 cells were co-transfected with a vector encoding His₆-tagged ubiquitin (34) and a vector encoding HA-tagged β -catenin (Fig. 3). 48 hr after transfection, the cells were treated with the proteasome specific inhibitor, Lactacystin, for 6 hr. Ubiquitinated proteins were purified by Ni-NTA chromatography (34) and Western blotted with anti-HA antibody (Fig. 4). β -catenin was found to accumulate as high- molecular weight ubiquitinated conjugates, in response to the proteasome-specific inhibitor Lactacystin. These observations demonstrate that cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.

Aim 2. To establish an *in vitro* cell-free model to study β -catenin ubiquitination and degradation.

In vitro ubiquitination and degradation assays were established according to published protocols (29,35,36) and with the help of our collaborators Drs. Aaron Ciechanover and Allan Weissman.

1. Cytosol that included membrane and/or particulate material was able to ubiquitinate β -catenin more efficiently than a S100 preparation that lacked them (Fig. 5).
2. Cytosol extracted from cells in different phases of the cell cycle, strikingly varied in their ability to ubiquitinate β -catenin (Fig. 6).
3. The most efficient ubiquitination activity was observed in the extracts from cells in M-phase (Fig. 6).

Aim 3. To test the hypothesis that the tumor suppressor adenomatous polyposis coli (APC) gene product is involved in the ubiquitin-proteasome pathway that regulates β -catenin.

1. Recombinant APC constructs help degrade β -catenin in SW480 (APC^{-/-}) cell lysate, *in vitro*. APC constructs 4 and 25 (Fig.8) include a free-cysteine-HECT consensus of ubiquitin ligases, whereas APC 3 does not. Lane 6; In the presence of a proteasomal inhibitor, a high molecular weight band is observed, which probably is a mono-ubiquitinated β -catenin (Fig.10).

2. Anti-APC antibodies and N-ethyl Maleimide (NEM) (4) inhibit the ubiquitination of β -catenin, *in vitro* (Fig. 9).

3. In SW480 cells transfected with APC (Fig. 11), β -catenin was found to be stabilized as ubiquitinated conjugates, in response to lactacystin, a specific proteasomal inhibitor. In cells transfected with vector alone, the proteasomal inhibitor had no effect. However, in Lane 6, the APC 3 transfection did not seem to have worked well in this particular experiment. Further experiments monitoring the effect of vectors including APC constructs that lack the HECT domain are currently in progress.

Aim 4. To test the hypothesis that the APC gene product is an ubiquitin-ligase (E3)

In vitro reconstitution experiments with recombinant β -catenin, E1, E2, and various recombinant APC fragments (with/without the HECT consensus) have proved to be elusive and efforts to standardize reaction conditions continue with the help of Dr. Allan Weissman (NIICB, NIH).

Conclusions

1. Cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.
2. *In vitro*, cytosol that included membrane and/or particulate material ubiquitinated β -catenin more efficiently than a S100 preparation that lacked them.
3. Cytoplasmic extracts from M-phase cells displayed maximal ability to ubiquitinate β -catenin, *in vitro*.
4. Anti-APC antibodies and N-ethyl Maleimide (NEM) inhibit the ubiquitination of β -catenin, *in vitro*
5. Recombinant APC constructs help degrade β -catenin in SW480 (APC^{-/-}) cell lysate, *in vitro*.
6. In SW480 cells transfected with APC, β -catenin is stabilized as ubiquitinated conjugates, in response to a proteasome specific inhibitor.

Recommended Changes

The above observations lead to the question, "Do changes in physiologically relevant signaling, i.e. GSK3 β activity, lead to changes in the ubiquitin-proteasomal turnover of β -catenin?"

We hope to partially answer this question *in vivo*, by studying changes in β -catenin turnover in cells treated with inhibitors of GSK3 β activity, like Rapamycin and Wortmannin. Further analysis of GSK3 β activity, its effect on APC phosphorylation, and subsequent effects on β -catenin ubiquitination and stability will be addressed using the *in vitro* assays described below. For these experiments, pre-phosphorylated APC, de-phosphorylated APC, with/without purified GSK3 β , and GSK3 β inhibitory peptides will be used (these reagents were kindly provided by our collaborator Dr. Paul Polakis).

Preliminary studies on the cell cycle dependent fluctuations of β -catenin, APC, and GSK3 β are currently in progress.

Bibliography

1. Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler, K.W., Vogelstein, B., and Clevers, H. Constitutive transcriptional activation by a b-catenin-Tcf Complex in APC^{-/-} colon carcinoma. *Science*, 275: 1784-1787, 1997.
2. Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K.W. Activation of b-catenin/Tcf signaling in colon cancer by mutations in b-catenin or APC. *Science*, 275: 1787-1790, 1997.
3. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. Stabilization of b-catenin by genetic defects in melanoma cell lines. *Science*, 275: 1790-1792, 1997.
4. Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc. Natl. Acad. Sci. U. S. A.* 92: 3046-3050, 1995.
5. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. Binding of GSK3 beta to the APC-beta-catenin complex and regulation of complex assembly. *Science*, 272: 1023-1026, 1996.
6. Vlemminckx, K., Wong, E., Guger, K., Rubinfeld, B., Polakis, P., and Gumbiner, B. Adenomatous polyposis coli tumor suppressor protein has signaling activity in xenopus laevis embryos resulting in the induction of an ectopic dorsoanterior axis. *J. Cell Biol.* 136: 411-420, 1997.
7. Moser, A.R., Mattes, E.M., Dove, W.F., Lindstrom, M.J., Haag, J.D., and Gould, M.N. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. *Proc. Natl. Acad. Sci. U. S. A.* 90: 8977-8981, 1993.
8. Papkoff, J., Rubinfeld, B., Schryver, B., and Polakis, P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. *Mol. Cell Biol.* 16: 2128-2134, 1996.
9. Hinck, L., Nelson, W.J., and Papkoff, J. Wnt-1 modulates cell-cell adhesion in mammalian cells by stabilizing beta-catenin binding to the cell adhesion protein cadherin. *J. Cell Biol.* 124: 729-741, 1994.
10. Behrens, J., von Kries, J.P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. Functional interaction of b-catenin with the transcription factor LEF-1. *Nature*, 382: 638-642, 1996.
11. Peifer, M. Regulating cell proliferation: as easy as APC. *Science*, 272: 974-975, 1996.
12. Peifer, M. Beta Catenin as oncogene: The smoking gun. *Science*, 275: 1752-1753, 1997.

13. Whitehead, I., Kirk, H., and Kay, K. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. *Mol. Cell Biol.* 15: 704-710, 1995.
14. Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. *Science*, 251: 1451-1455, 1991.
15. Frixen, U.H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and Birchmeier, W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. *J. Cell Biol.* 113: 173-185, 1991.
16. Gumbiner, B.M. and McCrea, P.D. Catenins as mediators of the cytoplasmic functions of cadherins. *J. Cell Sci. Suppl.* 17: 155-158, 1994.
17. Cowin, P. and Burke, B. Cytoskeleton-membrane interactions. *Curr. Opin. Cell Biol.* 8: 56-65, 1996.
18. Hoschuetzky, H., Aberle, H., and Kemler, R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. *J. Cell Biol.* 127: 1375-1380, 1994.
19. Shibamoto, S., Hayakawa, K., Takeuchi, T., Hori, N., Oku, K., Miyazawa, N., Kitamura, M., Takeichi, M., and Ito, F. Tyrosine phosphorylation of beta catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. *Cell Adh. Commun.* 1: 295-305, 1994.
20. Behrens, J., Vakaet, L., Friis, R., Winterhager, E., Van Roy, F., Mareel, M.M., and Birchmeier, W. Loss of Epithelial Differentiation and Gain of Invasiveness Correlates with Tyrosine Phosphorylation of the E-Cadherin/B-Catenin Complex in Cells Transformed with a Temperature-Sensitive v-SRC Gene. *JCB*, 120: 757-766, 1993.
21. Sommers, C.L., Gelmann, E.P., Kemler, R., Cowin, P., and Byers, S.W. Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cell lines. *Cancer Res.* 54: 3544-3552, 1994.
22. Munemitsu, S., Albert, I., Rubinfeld, B., and Polakis, P. Deletion of an amino-terminal sequence stabilizes b-catenin in vivo and promotes hyperphosphorylation of the adenomatous polyposis coli tumor suppressor protein. *Mol. Cell Biol.* 16: 4088-4094, 1996.
23. Funayama, N., Fagotto, F., McCrea, P., and Gumbiner, B.M. Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling. *J. Cell Biol.* 128: 959-968, 1995.
24. McCrea, P.D., Briher, W.M., and Gumbiner, B.M. Induction of a secondary body axis in *Xenopus* by antibodies to beta-catenin. *J. Cell Biol.* 123: 477-484, 1993.

25. Reise, J., Yu, X., Munnerlyn, A., Eresh, S., Hsu, S., Grosschedl, R., and Bienz, M. LEF-1, a nuclear factor co-ordinating signaling inputs from wingless and decapentaplegic. *Cell*, 88: 777-787, 1997.
26. Su, L., Vogelstein, B., and Kinzler, K.W. Association of the APC tumor suppressor protein with catenins. *Science*, 262: 1734-1737, 1993.
27. Baeg, G., Matsumine, A., Kuroda, T., Bhattacharjee, R.N., Miyaashiro, I., Toyoshima, K., and Akiyama, T. The tumor suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase. *EMBO J*, 14: 5618-5625, 1995.
28. Ciechanover, A. The ubiquitin-proteasome pathway. *Cell*, 79: 13-21, 1994.
29. Orian, A., Whiteside, S., Israel, A., Stancovski, I., Schwartz, A.L., and Ciechanover, A. Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. *J. Biol. Chem.* 270: 21707-21714, 1995.
30. Stancovski, I., Gonen, H., Orian, A., Schwartz, A.L., and Ciechanover, A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. *Mol. Cell Biol.* 15: 7106-7116, 1994.
31. Scheffner, M., Huibregtse, J.M., Vierstra, R.D., and Howley, P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell*, 75: 495-505, 1995.
32. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell*, 78: 761-771, 1994.
33. Grenfell, S.J., Trausch Azar, J.S., Handley Gearhart, P.M., Ciechanover, A., and Schwartz, A.L. Nuclear localization of the ubiquitin-activating enzyme, E1, is cell-cycle-dependent. *Biochem. J.* 300: 701-708, 1993.
34. Treier, M., Staszewski, L.M., and Bohmann, D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the delta domain. *Cell*, 78: 787-798, 1995.
35. Shkedy, D., Gonen, H., Bercovich, B., and Ciechanover, A. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. *FEBS Lett.* 348: 126-130, 1994.

36. Gonen, H., Stancovski, I., Shkedy, D., Hadari, T., Bercovich, B., Bengal, E., Mesilati, S., Abu Hatoum, O., Schwartz, A.L., and Ciechanover, A. Isolation, characterization, and partial purification of a novel ubiquitin-protein ligase, E3. Targeting of protein substrates via multiple and distinct recognition signals and conjugating enzymes. *J. Biol. Chem.* 271: 302-310, 1996.
37. Blumenfeld, N., Gonen, H., Mayer, A., Smith, C.E., Siegel, N.R., Schwartz, A.L., and Ciechanover, A. Purification and characterization of a novel species of ubiquitin-carrier protein, E2, that is involved in degradation of non-"N-end rule" protein substrates. *J. Biol. Chem.* 269: 9574-9581, 1994.
38. Zhang, M., Zou, Z., Maass, N., and Sager, R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. *Cancer Res.* 55: 2537-2541, 1995.
39. Stampfer, M.R., Pan, C.H., Hosoda, J., Bartholomew, J., Mendelsohn, J., and Yaswen, P. Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. *Exp. Cell Res.* 208: 175-188, 1993.
40. Urbani, L., Sherwood, S.W., and Schimke, R.T. Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization. *Exp. Cell Res.* 219: 159-168, 1995.
41. Igawa, M., Rukstalis, D.B., Tanabe, T., and Chodak, G.W. High levels of nm23 expression are related to cell proliferation in human prostate cancer. *Cancer Res.* 54: 1313-1318, 1994.
42. Levenson, V. and Hamlin, J.L. A general protocol for evaluating the specific effects of DNA replication inhibitors. *Nucleic. Acids. Res.* 21: 3997-4004, 1993.
43. Brandeis, M. and Hunt, T. The proteolysis of mitotic cyclins in mammalian cell persists from the end of mitosis until the onset of S-phase. *EMBO. J.* 15: 5280-5289, 1996

ADDENDA





Figure 1. β -catenin accumulates as high- molecular weight ubiquitinated conjugates, in response to the proteasomal inhibitor ALLN and Lactacystin. ALLM is the negative control.

In the right panel, β -catenin was immunoprecipitated with a C-terminal monoclonal antibody from a NP-40 lysate, and Western blotted with anti-ubiquitin antibody. NI: Non-Immune, β : β -catenin.



AUTORADIOGRAPH OF IMMUNOPRECIPITATED [³⁵S] β CATENIN

Figure 2. Pulse chase in E36ts20 cells harboring a thermolabile Ubiquitin activating (E1) enzyme. When grown at the non-permissive temperature, the half-life of β -catenin is extended.

EXPERIMENTAL DESIGN :




Figure 3. Experimental design to test the hypothesis that cytoplasmic β -catenin is regulated at the level of stability by the ubiquitin-proteasome pathway.




Figure 4. β -catenin accumulates as high- molecular weight ubiquitinated conjugates, in response to the proteasomal inhibitor Lactacystin.




Figure 5. *In vitro* β -catenin ubiquitination assay. Cytosol that included membrane material (vesicular lysate) ubiquitinated β -catenin more efficiently than a S100 preparation that lacked them.





Figure 6. *In vitro* β -catenin ubiquitination assay. Cytosol extracted from cells in different phases of the cell cycle, strikingly varied in their ability to ubiquitinate β -catenin. The most efficient ubiquitination activity was observed in the extracts from cells in M-phase.


The second β -catenin binding repeat of APC contains a free cysteine consensus region present in the HECT family ubiquitin ligases

	~ SH
	L P L ▼ V V Y
HECT domain	P L X X X X <u>C</u> X X X S X L X X F
Human APC	P L X X X X <u>C</u> X X X S X L X X F
	1387
Mouse APC	P L X X X X <u>C</u> X X X S X L X X F
Xenopus APC	P L X X X X <u>C</u> X X X S X L X X F

Figure 8.


APC Functional Domains and Constructs





Anti- β-Catenin Western blot

Figure 9. *In vitro* degradation assay. Anti-APC antibodies and N-ethyl maleimide (NEM) inhibit the *in vitro* degradation β-catenin



Anti β-catenin Western blot

Figure 10. *In vitro* β-catenin ubiquitination assay. Recombinant APC constructs help degrade β-catenin in SW480 (APC^{-/-}) cell lysate, *in vitro*. Constructs 4, 25, and 2 include a free-cysteine-HECT consensus of ubiquitin ligases. APC 3 does not. Lane 6; In the presence of a proteasomal inhibitor, a high molecular weight band is observed, which probably is a mono-ubiquitinated β-catenin

EXPERIMENTAL DESIGN :





Figure 11. SW480 cells (APC^{-/-}) were co-transfected with a vector encoding His₆-tagged ubiquitin and a vector encoding APC 25 (the smallest construct including the free cysteine consensus) , APC 3, or vector alone. 24 hr after transfection, cells were treated with the proteasome-specific inhibitor, Lactacystin for 6 hr. Ubiquitinated proteins were purified by Ni-NTA chromatography, and Western blotted with anti-β-catenin antibody. In cells transfected with APC 25, β-catenin was found to be stabilized as ubiquitinated conjugates, in response to a specific proteasomal inhibitor. In cells transfected with vector alone, the proteasomal inhibitor had no effect probably because the native ubiquitination machinery is not functional. Lane 6; the APC 3 transfection did not seem to have worked well in this particular experiment. Experiments monitoring the effect of vectors including APC constructs that lack the HECT domain are currently in progress.